USpharma Ltd., a pharmaceutical development and manufacturing company commercializing several novel delivery platforms, announces a significant growth equity investment by 1315 Capital, a Philadelphia-based healthcare growth equity firm. USpharma leverages advanced and patented formulation technologies, including its next generation soft chewable dosage forms and the unique capabilities of its 150,000 square foot US-based GMP facility, to develop and manufacture innovative products across multiple pharmaceutical and supplement markets. This capital infusion will enable USpharma to accelerate the development and commercialization of its pipeline and scale operations to meet growing market demand.
Read the full article: USpharma Ltd. Secures Growth Capital Investment by 1315 Capital //
Source: https://www.prnewswire.com/news-releases/uspharma-ltd-secures-growth-capital-investment-by-1315-capital-302493534.html